ADAPY (Adaptimmune Therapeutics) 6-1 Month Momentum %: 104.91% (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics 6-1 Month Momentum %?

Adaptimmune Therapeutics ADAPY +5.80% 6-1 Month Momentum % is 104.91% as of Aug. 26, 2026.

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-26), Adaptimmune Therapeutics's 6-1 Month Momentum % is 104.91%.

The industry rank for Adaptimmune Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

ADAPY's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -17.46 vs ADAPY: 104.91

Adaptimmune Therapeutics  (OTCPK:ADAPY) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Adaptimmune Therapeutics 6-1 Month Momentum % Related Terms

ADAPY vs BCLI, APRE, JSPR: 6-1 Month Momentum % Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics 6-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's 6-1 Month Momentum % falls into.


Adaptimmune Therapeutics  (OTCPK:ADAPY) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-1 Month Momentum % →
What does a 6-1 Month Momentum % of 104.91% mean?
Adaptimmune Therapeutics (ADAPY) has a 6-1 Month Momentum % of 104.91% as of Aug. 26, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' 6-1 Month Momentum % too high?
Adaptimmune Therapeutics' current 6-1 Month Momentum % is 104.91%.
How does Adaptimmune Therapeutics' 6-1 Month Momentum % compare to BCLI and APRE?
Adaptimmune Therapeutics' 6-1 Month Momentum % of 104.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current 6-1 Month Momentum % is 104.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current 6-1 Month Momentum % of 104.91%. The current 6-1 Month Momentum % is 104.91%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current 6-1 Month Momentum % is 104.91% as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].